Dr. Yanqiu Zhao 赵艳秋
Chief Physician
Department of Integrated Traditional Chinese and Western Medicine Oncology, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of thoracic malignancies, including esophageal cancer and lung cancer.
Dr. Zhao is Chief Physician and Deputy Director of Internal Medicine at Henan Cancer Hospital. Holding a Master of Medicine from Sun Yat-sen University of Medical Sciences (1989), Dr. Zhao has over 20 years of experience in medical oncology. From 2011 to 2013, Dr. Zhao completed advanced training at the Dana-Farber Cancer Institute, Harvard Medical School.
Professional roles
- Member, Esophageal Cancer Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Internal Medicine Professional Committee, Henan Medical Association
Name order: in Chinese the family name comes first (Zhao Yanqiu). Papers usually list the name as Yanqiu Zhao or Zhao Y.
Selected publications
105 papers on PubMed matched by name and affiliation; 17 as first or senior author since 2016. Most recent first- or senior-author papers:
- N Engl J Med, 2026 (first author): Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy. PubMed 42734213
- Front Oncol, 2025 (senior author): First-line treatment options for PD-L1-negative lung adenocarcinoma: a real-world analysis. PubMed 40535117
- Aging (Albany NY), 2025 (senior author): Retraction of: Glypican-1-targeted and gemcitabine-loaded liposomes enhance tumor-suppressing effect on pancreatic cancer. PubMed 40331642
- BMC Med Genomics, 2024 (senior author): Case report: response to immunotherapy and association with the fh gene in hereditary leiomyomatosis and renal cell cancer-associated renal cell cancer. PubMed 39160519
- Heliyon, 2024 (senior author): An epidermal growth factor receptor-mutated lung adenocarcinoma patient with brain lesions resisted to osimertinib monotherapy but achieved more than 4 years of survival in osimertinib plus bevacizumab metronomic treatment. PubMed 38298673
- EClinicalMedicine, 2023 (first author): AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. PubMed 37593227
- EClinicalMedicine, 2023 (first author): A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study). PubMed 36712888
- Thorac Cancer, 2022 (senior author): Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements. PubMed 35212154
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion